Publications by authors named "Werner Scheithauer"

Claim this Profile
I
Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer - A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial.
Kathrin Heinrich, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Werner Scheithauer

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study.
Leonard B Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, Alena B Gesenhues, Nina Hesse, Werner Scheithauer

Eur Radiol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Dominik P Modest, Thomas Decker, Werner Scheithauer

Br J Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259].
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, Christoph B Westphalen Benedikt, Kathrin Heinrich, Werner Scheithauer

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, Ludwig Fischer von Weikersthal, Markus M Lerch, Werner Scheithauer

Int J Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Werner Scheithauer

Br J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, Werner Scheithauer, Gary Middleton

Oncologist· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Christoph Schulz, Volker Heinemann, Kathrin Heinrich, Michael Haas, Julian W Holch, Werner Scheithauer

Anticancer Drugs· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, Christoph B Westphalen, Kathrin Heinrich, Werner Scheithauer

Eur J Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC.
Daniela Bianconi, Merima Herac, Florian Posch, Margit Schmeidl, Matthias Unseld, Werner Scheithauer

Ther Adv Med Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.
Florian Moik, Florian Posch, Ella Grilz, Werner Scheithauer, Ingrid Pabinger

Thromb Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients.
Markus Kieler, Matthias Unseld, Daniela Bianconi, Martin Schindl, Gabriela V Kornek, Werner Scheithauer

J Clin Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Werner Scheithauer, Paul Martin Putora, Birgit Grünberger, Wolfgang Eisterer, Ewald Wöll

Therap Adv Gastroenterol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid.
Markus Kieler, Matthias Unseld, Daniela Bianconi, Werner Scheithauer, Gerald W Prager

Ther Adv Med Oncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores.
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, György Bodoky, Thomas Ruhstaller, Werner Scheithauer

Ther Adv Med Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
Matthias Unseld, Magdalena Drimmel, Alexander Siebenhüner, Andreas Gleiss, Daniela Bianconi, Werner Scheithauer

Clin Colorectal Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Werner Scheithauer

Int J Cancer· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Emil Ter Veer, L Bengt van Rijssen, Marc G Besselink, Rosa M A Mali, Jordan D Berlin, Werner Scheithauer

Lancet Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306).
Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Werner Scheithauer

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.
Noemi Pavo, Markus Raderer, Georg Goliasch, Raphael Wurm, Guido Strunk, Werner Scheithauer

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel.
Daniela Bianconi, Gerwin Heller, Daniel Spies, Merima Herac, Andreas Gleiss, Werner Scheithauer

Sci Rep· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Werner Scheithauer

Int J Cancer· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial.
Josep Tabernero, Volker Kunzmann, Werner Scheithauer, Michele Reni, Jack Shiansong Li

Onco Targets Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease.
Markus Kieler, Werner Scheithauer, Christoph C Zielinski, Andreas Chott, Ali Al-Mukhtar

ESMO Open· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis